EUVIMEDEUVIMED entdecken
Crossref

A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy

Yogalakshmi Sabapathy, Balaji Ramachandran, Priya Ramanathan, Shirley Sundersingh, Nazeer Yasin, Narayanan Madaboosi, Guhan Jayaraman, Pazhanivel Natesan, Gopal Gopisetty, Rajkumar Thangarajan

Biochemical Pharmacology · 2026-12 · 254 · 118591

DOI: 10.1016/j.bcp.2026.118591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Yogalakshmi Sabapathy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (WIA), Chennai, India. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ewing sarcoma (ES) is an aggressive paediatric malignancy characterised by high CD99 expression and limited targeted therapeutic options. In this study, we developed a recombinant anti-CD99 Cancer Institute Antibody (CIAb-anti-CD99) by isotype switching a hybridoma-derived IgM/κ antibody to an IgG2a/κ format to improve manufacturability and therapeutic applicability. Recombinant CIAb-anti-CD99 was expressed in CHO-K1 cells and retained specific recognition of CD99, as demonstrated by immunofluorescence, flow cytometry, Western blotting, and immunohistochemistry. Functionally, CIAb-anti-CD99 increased the Annexin V/PI-positive cell population and inhibited proliferation and clonogenic growth of CD99-positive ES cells in vitro. To evaluate the potential of CIAb-anti-CD99 for targeted drug delivery, CIAb-anti-CD99 was conjugated to doxorubicin to generate a CD99-targeted antibody-drug conjugate (CIAb-Dox). In vivo biodistribution studies demonstrated tumour localisation and prolonged retention of CIAb-anti-CD99 in A673 xenograft tumours. Therapeutic evaluation in an A673 cell line-derived xenograft (CDX) model showed that CIAb-Dox significantly suppressed tumour growth compared with vehicle and antibody monotherapy. Histopathological analysis demonstrated lower viable tumour content and greater tumour necrosis in CIAb-Dox-treated tumours. Quantitative immunohistochemical analysis further showed a significant reduction in the Ki67-positive proliferative index and increased cleaved PARP staining, consistent with apoptosis-associated cellular changes. CIAb-Dox demonstrated enhanced antitumour activity while maintaining a favourable tolerability profile. Collectively, these findings provide preclinical evidence supporting further investigation of CD99-directed antibody-drug conjugates. CIAb-anti-CD99 represents a functionally active CD99-targeting antibody, while CIAb-Dox warrants further evaluation in additional Ewing sarcoma models, together with mechanistic, pharmacokinetic, and comprehensive analytical studies.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugateCD99CHO cellsEwing sarcomaPreclinical evaluationRecombinant antibody

Autor:innen und Institutionen

  • Cancer Institute (WIA), Chennai, India.
  • Cancer Institute (WIA), Chennai, India. Electronic address: r.balaji@cancerinstitutewia.org.
  • Indian Institute of Technology Madras, Chennai, India.
  • Tamil Nadu Veterinary and Animal Sciences University, Chennai, India.
  • Cancer Institute (WIA), Chennai, India. Electronic address: ggopisetty@gmail.com.

Förderung

  • Science and Engineering Research Board

Zitieren

APA

Sabapathy, Y., Ramachandran, B., Ramanathan, P., Sundersingh, S., Yasin, N., Madaboosi, N., Jayaraman, G., Natesan, P., Gopisetty, G., & Thangarajan, R. (2026). A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy. Biochemical Pharmacology, 254, 118591. https://doi.org/10.1016/j.bcp.2026.118591

Vancouver

Sabapathy Y, Ramachandran B, Ramanathan P, Sundersingh S, Yasin N, Madaboosi N, et al. A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy. Biochemical Pharmacology. 2026;254:118591. doi:10.1016/j.bcp.2026.118591

BibTeX
@article{Sabapathy2026,
  author = {Sabapathy, Yogalakshmi and Ramachandran, Balaji and Ramanathan, Priya and Sundersingh, Shirley and Yasin, Nazeer and Madaboosi, Narayanan and Jayaraman, Guhan and Natesan, Pazhanivel and Gopisetty, Gopal and Thangarajan, Rajkumar},
  title = {A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {254},
  pages = {118591},
  doi = {10.1016/j.bcp.2026.118591}
}
Kostenlos starten →